Market Overview

J.P. Morgan Reiterates Neutral Rating on Bristol Myers Squibb Co.

Share:
Related BMY
Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place
Is Big Pharma Hinting At A SMID-Cap Biotech Rally?
Tracking Kahn Brothers Portfolio - Q4 2015 Update (Seeking Alpha)

In a report published Monday, J.P. Morgan & Co. reiterated its Neutral rating on Bristol Myers Squibb Co. (NYSE: BMY).

J.P. Morgan noted, “Maintain Neutral rating. We continue to view pipeline progression as the key driver for BMY shares and see a number of important events in 2013 including the launch of Eliquis, longer-term data on the company's PD-1 program as well as CV outcomes data for Onglyza. That said, we believe current valuation adequately reflects this with the stock trading at 18x trough 2013E EPS and remain Neutral on BMY shares.”

Bristol Myers Squibb Co. closed on Friday at $31.90.

Latest Ratings for BMY

DateFirmActionFromTo
Jan 2016BMO CapitalDowngradesOutperformMarket Perform
Jan 2016BerenbergUpgradesHoldBuy
Jan 2016JefferiesMaintainsHold

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Reiteration Analyst Ratings

 

Related Articles (BMY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters